Why McKesson Corporation (MCK) Stock Rose 7.0% on Nov 4, 2026
What happened
McKesson rallied 6.85% to $1,068.05 ahead of second-quarter fiscal 2027 earnings results scheduled for release after market close today, November 4, according to investing.com and finance.yahoo.com. Investors are positioned for the report citing analyst expectations of $10.69 EPS on $110.11B revenue, with particular focus on GLP-1 medication distribution volumes—which surged 24% year-over-year to $15B last quarter—and recent strategic moves including its $1.4B stake in Option Care Health.
McKesson's Q2 fiscal 2027 earnings release and 4:30 PM ET conference call today; key metrics to monitor are GLP-1 distribution volume trends and updated full-year guidance.
Other developments that session
McKesson Corporation (MCK) filed a new 8-K on November 4, 2026. The audit found no price movement data or details of the filing's specific content.
McKesson Corporation (MCK) reported EPS of $11.68 vs. consensus estimate of $10.72, beating by 9.0% for Q2 FY2027.
Frequently asked questions
Why did McKesson Corporation (MCK) stock rise on Nov 4, 2026?
McKesson rallied 6.85% to $1,068.05 ahead of second-quarter fiscal 2027 earnings results scheduled for release after market close today, November 4, according to investing.com and finance.yahoo.com. Investors are positioned for the report citing analyst expectations of $10.69 EPS on $110.11B revenue, with particular focus on GLP-1 medication distribution volumes—which surged 24% year-over-year to $15B last quarter—and recent strategic moves including its $1.4B stake in Option Care Health.
How much did MCK stock rise on Nov 4, 2026?
MCK rose 7.0% during the Nov 4, 2026 trading session.
